Kaitlyn ANDREANO,Ching-yi CHANG,Donald P. MCDONNELL,Stephanie L. GAILLARD
申请号:
US16341033
公开号:
US20190231718A1
申请日:
2017.10.10
申请国别(地区):
US
年份:
2019
代理人:
摘要:
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women, and in particular embodiments, methods for treating ER+ cancers having gain of function mutations in the ESR1 ligand binding domain, with an effective amount of a compound selected from the group consisting of raloxifene, bazedoxifene, tamoxifen, etacstil, and fulvestrant, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.